- Home
- CVBF vs LEGN Comparison
CVBF vs LEGN Comparison
Compare CVBF & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CVBF | LEGN |
|---|---|---|
| Founded | 1974 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CVBF | LEGN |
|---|---|---|
| Price | $22.57 | $21.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $26.08 | ★ $45.62 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 10-21-2026 | 11-10-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | ★ 5.56 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.38 | $39.73 |
| Revenue Next Year | $14.66 | $23.42 |
| P/E Ratio | $34.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.01 | $16.24 |
| 52 Week High | $23.41 | $37.50 |
Technical Indicators
Market Signals| Indicator | CVBF | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 60.31 |
| Support Level | $22.22 | $17.08 |
| Resistance Level | $23.27 | $21.99 |
| Average True Range (ATR) | 0.43 | 1.17 |
| MACD | 0.09 | 0.42 |
| Stochastic Oscillator | 70.84 | 71.77 |
Price Performance
Historical ComparisonAbout CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit. It is a community bank with one reportable operating segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.